Online inquiry

IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3642MR)

This product GTTS-WQ3642MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FGFR2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000141.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2263
UniProt ID P21802
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3642MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ642MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 8c10
GTTS-WQ12071MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MOR-00208
GTTS-WQ4712MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-986168
GTTS-WQ7553MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GC33
GTTS-WQ13580MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA QAX-576
GTTS-WQ15463MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA U3-1287
GTTS-WQ15546MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ12223MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MOXR-0916
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW